DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1947)

Malignant Melanoma | Landscape & Forecast | Disease Landscape & Forecast

Malignant Melanoma | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances. Owing to these advances, primarily in immuno- and targeted cancer therapies, the malignant melanoma market has become increasingly crowded with novel treatments expanding therapy options for patients, and segmenting the market according to BRAF-mutation status. While heavily dominated by immune checkpoint inhibitors, such as Merck & Co.’s market-leading Keytruda and Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, opportunities exist for novel agents specifically targeting the underpenetrated adjuvant and BRAF wild-type metastatic setting. With a shift toward combination therapy, doublet and triplet therapy, and the introduction of novel agents for later lines, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.

Questions Answered:

  •  How large are the clinically and commercially relevant drug-treatable malignant melanoma populations and how will drug-treatment rates change over time?
  •  What is the current state of treatment in malignant melanoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in the malignant melanoma market? What does the early-phase pipeline look like?
  • What are the drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • March 2019
      • December 2018
      • October 2018
      • August 2018
      • May 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Malignant Melanoma?
        • What Factors Are Constraining the Market for Malignant Melanoma?
      • Segment-Specific Trends
        • Resectable Malignant Melanoma: Stage IIB-III
        • First-Line Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
        • First-Line Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
        • Previously Treated Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
        • Previously Treated Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Disease Pathophysiology
        • Progression of Malignant Melanoma
      • Staging and Classification
        • Classification and Staging of Malignant Melanoma
        • Histopathological and Clinical Prognostic Factors for Malignant Melanoma
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Malignant Melanoma
        • Recurrent Incident Cases on Malignant Melanoma
        • Drug-Treatable Populations of Malignant Melanoma
        • Drug-Treated Populations of Malignant Melanoma
    • Current Treatment
      • Key Findings
        • Treatment Overview
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
        • BRAF/MEK Inhibitors
        • Oncolytic Viral Therapy
        • Cytokines
        • Cytotoxic Agents
      • Medical Practice
        • Drug-Treatable Populations
        • Treatment Guidelines
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Malignant Melanoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Malignant Melanoma
        • Immune Checkpoint Inhibitors
        • Therapeutic Vaccines
        • T-Cell-Based Therapy
        • Intralesional Therapy
        • Angiogenesis Inhibitors
        • Cytokines
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Malignant Melanoma
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Malignant Melanoma Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Ann-Marie Looney, M.Sc., Ph.D; Oliver Blandy
  • Ann-Marie Looney, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr Looney worked as a postdoctoral researcher for the National Children’s Research Centre and the Irish Centre for Fetal and Neonatal Translational Research, Ireland where her work centred on the discovery and validation of biomarkers of early childhood injury and disease, with a specific focus on early childhood obesity, neonatal brain injury and autism spectrum ; She has a in Neuroscience, a by research in molecular biology and a in clinical and translational research from University College Cork, Ireland.

  • Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.

Purchase Report

Recent reports:
You may also be interested in: